The question comes before the panel
A wellness panel can give you numbers without explaining why those numbers were measured. Before comparing sermorelin programs, I would ask what clinical question the testing is intended to answer. Screening for a possible pituitary disorder, reviewing an established diagnosis and checking a marker during a proposed wellness treatment are different tasks. They should not become one decision merely because they appear in the same checkout.
The Endocrine Society’s adult growth hormone deficiency guideline says confirmation usually requires stimulation testing, with defined exceptions. Its subject is a diagnosed deficiency, not a promise to reverse ordinary aging. A service offering an IGF-1 result therefore has not, by that fact alone, established either a diagnosis or the right treatment. [1]
Why the clinical history changes the interpretation
The 2011 guideline identifies circumstances such as structural pituitary disease, treatment in that area, head trauma and other pituitary hormone deficiencies as reasons to consider evaluation. It also describes factors that complicate interpretation of a low IGF-1 result, including liver disease, poorly controlled diabetes and oral estrogen use. Those details belong with the clinician’s assessment, rather than beside a shopping-page cutoff. [2]
I would bring the original report and the reason it was ordered to that conversation. Ask whether an unexpected result needs confirmation, what else could explain it and whether the clinical history changes the next step. Do not change medicines or prepare for a test from a website’s general instructions. The person arranging the evaluation should explain the preparation for the actual test.
A stimulation test asks a different question
The 2016 hypopituitarism guideline recommends stimulation testing in suspected growth hormone deficiency and says a single GH measurement is not helpful. It also calls for appropriate BMI-related interpretation and describes circumstances where additional biochemical testing is unnecessary. This is a clinical framework, not a universal instruction that every tired adult should buy a stimulation test. [3]
Our explanation of BMI and stimulation-test thresholds looks at one source of interpretation differences. The laboratory comparison addresses another. Neither page can convert a result into a diagnosis. Their purpose is to make the conversation about an existing test more precise.
Three records worth keeping separate
| Record | What it tells you | Question to bring |
|---|---|---|
| Laboratory report | A measured value and the laboratory’s reference interval | Why was this test chosen, and does it need confirmation? |
| Clinical assessment | How the result fits the person’s history and other findings | What diagnosis or uncertainty are we addressing? |
| Proposed care plan | The treatment, review process and expected outcome | What would make us continue, change or stop? |
A diagnosis still does not select a commercial program
The adult deficiency guideline discusses growth hormone replacement. That is not a blanket endorsement of compounded sermorelin or a commercial anti-aging package. The treatment identity matters just as much as the diagnosis. Ask the clinician to name the exact proposed medicine and explain which evidence supports its use in your situation. [1]
I would keep the clinical recommendation on one page and the purchase terms on another. The Nuform review separates physician-fee rules from medication purchases; the Yucca review separates monthly and quarterly commitments. Those comparisons can clarify what you would buy. They cannot establish what a hormone result means.
What I would take to the appointment
Use the appointment brief to write three questions: what are we investigating, what would change the interpretation and what outcome would we review? Add who will discuss the result and how you can contact that person. A portal showing a number is less useful than an agreed explanation of what happens next.
If a provider recommends more testing, ask what decision depends on the answer and which costs are included. If a treatment is proposed, ask how benefits, adverse effects and uncertainty will be reviewed together. Our marker-versus-benefit analysis helps keep a rising number separate from an outcome you can feel or measure. A clear plan can acknowledge uncertainty without turning it into a sales promise.